CD30 protects EBV-positive diffuse large B-cell lymphoma cells against mitochondrial dysfunction through...

Area of Science:

• Oncology
• Virology
• Cell Biology

Background:

• Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL) has a poor prognosis.
• CD30 expression exacerbates poor outcomes in EBV+ DLBCL.
• The role of CD30 in EBV+ DLBCL pathogenesis is not fully understood.

Purpose of the Study:

• To investigate CD30 as a prognostic indicator in EBV+ DLBCL.
• To elucidate the functional role of CD30 in EBV+ DLBCL growth and survival.
• To uncover the molecular mechanisms linking CD30, mitophagy, and EBV+ DLBCL.

Main Methods:

• Retrospective cohort study analyzing CD30 positivity as a prognostic factor.
• CRISPR/Cas9 gene editing to create CD30 and BNIP3 knockout models.
• Analysis of EBV-encoded latent membrane protein 1 (LMP1) and NF-κB signaling pathways.
• Co-immunoprecipitation assays to assess protein interactions.
• Assessment of mitochondrial function and mitophagy.

Main Results:

• CD30 positivity is an independent prognostic indicator in EBV+ DLBCL.
• CD30 is critical for EBV+ DLBCL growth and survival, mediated by EBV LMP1 via NF-κB signaling.
• CD30 deficiency represses BNIP3 expression, impairs mitophagy, and causes mitochondrial dysfunction.
• BNIP3 knockout leads to proliferation defects and increased apoptosis sensitivity.

Conclusions:

• CD30 plays a crucial role in EBV+ DLBCL pathogenesis by regulating BNIP3-mediated mitophagy.
• Disruption of mitophagy is linked to adverse prognosis in EBV+ DLBCL.
• Targeting CD30 with therapies like brentuximab vedotin may improve outcomes for CD30+ EBV+ DLBCL patients.